Removing Two Drugs from BEACOPP Doesn't Change Outcomes

The results of a new study published in the Journal of Clinical Oncology suggest that Hodgkin's lymphoma patients may not have to receive a pair of chemotherapy drugs known to cause serious side effects.

The standard of care in the US for Hodgkin's in terms of chemotherapy is ABVD, but in other parts of the world, the standard is BEACOPP, developed by German researchers. It is an intense regimen, featuring seven drugs, including two from ABVD: bleomycin and vincristine.

In BEACOPP, patients are more likely to discontinue treatment because of one of these two drugs over other reasons because of adverse events or side effects. Among an analysis of 3,309 patients with Hodgkin lymphoma, Bleomycin was discontinued in 17.6 percent of patients and vincristine in 32.6 percent.

This new study suggests that, in BEACOPP, if you remove those two drugs, it doesn't have any effect on overall survival compared to patients who receive all of the drugs.

“Our analysis shows that discontinuation of bleomycin or vincristine was safe in the setting of the HD12 and HD15 trials," wrote study researchers Heinz Haverkamp, of the University Hospital of Cologne, Germany. "However, the reasons for this lack of effect on progression-free and overall survival remain unclear.”

The research team added that in one of the ongoing trials, they replaced the two drugs with Adcetris, and that “First interim results suggest favorable efficacy and tolerability of two modified BEACOPP regimens without bleomycin and vincristine as compared with conventional BEACOPP escalated.”

Source: Cancer Network

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap